Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) PT at $10.14

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have covered the stock in the last year is $10.14.

Several equities research analysts recently weighed in on AQST shares. Lake Street Capital reduced their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James Financial set a $7.00 price target on shares of Aquestive Therapeutics in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday. Finally, Oppenheimer started coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price target on the stock.

Aquestive Therapeutics Stock Up 1.5%

AQST stock opened at $3.40 on Friday. The company has a market capitalization of $337.72 million, a P/E ratio of -5.76 and a beta of 1.94. The company has a 50-day simple moving average of $2.82 and a 200 day simple moving average of $3.06. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. Equities analysts anticipate that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. New York State Common Retirement Fund raised its holdings in Aquestive Therapeutics by 713.3% during the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares during the period. MONECO Advisors LLC acquired a new stake in Aquestive Therapeutics during the 4th quarter worth about $156,000. SBI Securities Co. Ltd. acquired a new stake in Aquestive Therapeutics during the 4th quarter worth about $115,000. Charles Schwab Investment Management Inc. raised its holdings in Aquestive Therapeutics by 3.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after buying an additional 7,129 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Aquestive Therapeutics during the 4th quarter worth about $498,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.